CTNM — Contineum Therapeutics, Inc. Class A Common Stock

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is a biotechnology company listed on NASDAQ. It is led by Carmine N. Stengone MBA, MS, based in 3565 General Atomics Court, San Diego, CA, United States, 92121, with about 51 employees. Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.

Net income was -$12.8M. CTNM currently screens at market cap $429.6M.

Use this CTNM page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CTNM quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CTNM SEC filings page. Lician reads the product cache first so this HTML stays unique to Contineum Therapeutics, Inc. Class A Common Stock even when a live quote feed is slow.